Association between FDA black box warnings and Medicare formulary coverage changes

Area of Science:

• Pharmacoeconomics
• Drug safety
• Health policy

Background:

• FDA black box warnings highlight serious drug risks.
• Safer alternatives may exist for some high-risk medications.
• Medicare formularies dictate drug access for beneficiaries.

Purpose of the Study:

• To evaluate Medicare formulary changes after new FDA black box warnings.
• To determine if formularies restrict access to drugs with new safety concerns.
• To assess formulary responses when safer drug alternatives are available.

Main Methods:

• Retrospective analysis of Medicare Prescription Drug Plan Formulary files (2007-2013).
• Identification of drugs with FDA black box warnings for death/cardiovascular risk.
• Assessment of formulary restrictiveness (unrestrictive, restrictive, no coverage) pre- and post-warning.

Main Results:

• Nine drugs with safer alternatives received 10 new black box warnings.
• Formulary restrictiveness increased for 40-50% of drugs within 2 years.
• Most formularies (70%) remained unrestrictive for the majority of drugs after 2 years.

Conclusions:

• Medicare formularies showed increased restrictiveness for some high-risk drugs.
• Inconsistent formulary responses to safety warnings were observed.
• Access to medications with new black box warnings varied despite available alternatives.